Clinical TrialsManagement disclosed results from Part A of the ongoing Phase 1/2 trial, demonstrating tumor uptake of 177 in all nine patients with positive GD2 expression.
InnovationY-mAbs has chosen to transition to a new proprietary radiohapten, expanding access to a range of isotopes with theranostic applications.
Product DevelopmentY-mAbs Therapeutics is noted as the only company with pretargeting assets already in the clinic, which could lead to differentiated next-generation radiopharmaceutical products.